TrialSignal
Clinical trial intelligence report
An Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Patients With Recent-Onset Type 1 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00870818
Status
TERMINATED
Phase
NA
Sponsor
MacroGenics
Executive brief
Investment-Ready Snapshot
The study aimed to evaluate the long-term safety and efficacy of Teplizumab (MGA031), a monoclonal antibody, in patients with recent-onset Type 1 Diabetes Mellitus. The trial was sponsored by MacroGenics in collaboration with Eli Lilly and Company. It was terminated due to a business decision after enrolling 219 participants.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00870818
Indication
Type 1 Diabetes Mellitus
Modality
monoclonal antibody
Target
Type 1 Diabetes Mellitus
Intervention
Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.